Follow this innovation
[ via 
] [?]
Method and composition of Pegylated protein (FVIII)-Phosphoserine complex
University at Buffalo - The State University of New York
posted on 10/20/2009
These novel compositions provide for enhanced delivery of protein therapeutics. Proteins (e.g. recombinant Factor VIII) associated with LIPRO-FORM exhibited improved pharmacokinetic profiles and higher efficacies in animal models. With characteristics such as lowered immunogenicity and increased circulation time, LIPRO-FORM provides significant potential advantages including a reduction in the frequency of administration, an abatement of inhibitor development and an extension of patent life.
Detailed Description
File Number: 6031
Disease: Blood and Lymphatic System
Other Information: Principal Investigator: SV Balasubramanian
This innovation currently is not available for online licensing. Please contact Tim Dee at University at Buffalo - The State University of New York for more information.
request more info
ProfileFind more innovations
